Wat is de prijs voor Organicell Regenerative Medicine, Inc. (OCEL)

Het prijs van Organicell Regenerative Medicine, Inc. (OCEL) is $1.77

Wat is de marktkapitalisatie voor Organicell Regenerative Medicine, Inc. (OCEL)

Marktkapitalisatie voorOrganicell Regenerative Medicine, Inc. (OCEL) is $12.89M

Organicell Regenerative Medicine, Inc. (OCEL) Aandelensplitsingen

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering biological therapies for degenerative conditions. Their primary investigational product is Zofin, an acellular biological treatment sourced from perinatal material. This therapeutic is specifically processed to preserve its inherent microRNAs, without the inclusion of any artificial additives or diluents. Zofin is currently undergoing Phase I/II clinical evaluation for its efficacy against COVID-19. Beyond its core drug development, Organicell also offers independent educational, promotional, and marketing solutions to various healthcare sectors, including medical, anti-aging, and regenerative service providers. The company maintains key research collaborations: one with the Centers for Disease Control and Prevention (CDC) to explore Zofin's anti-inflammatory and anti-infective capabilities in experimental influenza models, and another with Oklahoma State University to assess Zofin's potential in treating severe respiratory illnesses stemming from viruses with pandemic risk. Founded in 2011, this Miami, Florida-based company initially operated as Biotech Products Services and Research, Inc. It adopted its current name, Organicell Regenerative Medicine, Inc., in June 2018.

Jaar	Splitsing	Vermenigvuldiging	Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Splitsing

Vermenigvuldiging

Cumulatieve vermenigvuldiging

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Aantal aandelen splitsingen	Cumulatieve vermenigvuldiging	Land
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
CSL Limited CSL.AX	1	x3	AU
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR

Bedrijf

Aantal aandelen splitsingen

Cumulatieve vermenigvuldiging

Land